A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

Biliary Tract CarcinomaGallbladder Carcinoma

Interventions

DRUG

Selumetinib

DRUG

Cisplatin

DRUG

Gemcitabine

Trial Locations (1)

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors

lead

University Health Network, Toronto

OTHER